Apoptosis (programmed cell death) exerts critical roles in development, homeostasis and normal functioning of adult multi-cellular organisms[@b1]. It had been reported that various types of malignant diseases acquired ability to resist cell apoptosis, and that the regulatory defects of this cell-death pathway contribute to tumorigenesis, tumor cell invasion and metastasis[@b2]. Genetic variations of crucial genes in apoptosis pathway may thus influence the susceptibility to cancer.

The Fas--Fas ligand (FasL) system is the major pathway inducing cell and tissue apoptosis[@b3]. Ligation of Fas by either agonistic antibody or its natural ligand transmits a "death signal" to the target cells, potentially triggering apoptosis. Fas and FasL molecules play an important role in immune escape[@b4]. Decreased expression levels of Fas and FasL are associated with different malignancies. Increased expression of FasL may favor malignant transformation and progression[@b5].

Single nucleotide polymorphisms (SNPs) have been proposed to play an important role in the genetic susceptibility to cancer. Many studies have reported that functional SNPs can impact the risk of cancer. The functional mutations in the Fas and FasL genes that impair apoptotic signal transduction have been shown to be associated with an increased risk of many types of cancers, *e.g* esophageal squamous-cell carcinoma and lung cancer[@b6][@b7]. The Fas-FasL system plays important role in cancer initiation, development and progression. SNPs of Fas and/or FasL gene have been proposed to be significant in the genetic susceptibility to cancer through altering the expression of gene.

The aim of the present study was to analyze whether -844T/C (rs763110) polymorphism in FasL gene (GenBank accession no. Z96050) promoter confers host\'s susceptibility to cancers of esophageal squamous cell in south China. Meanwhile, the expression of FasL was analyzed to conform that the variation of -844T/C in FasL gene is able to significantly modify the levels of expression of FasL in patients. The polymorphism of Fas gene -1377 was analyzed to study whether susceptibility to esophageal cancer is influenced by FasL -844 SNP under the intervention of Fas -1377 SNP.

Results
=======

FasL polymorphism and the association with ESCC
-----------------------------------------------

This population-based case-control study included 248 patients with esophageal squamous cell carcinoma (ESCC) and 238 control subjects. All study subjects were south Chinese. Baseline clinical characteristics of cases and controls are summarized in [Table 1](#t1){ref-type="table"}. Cases were older than controls and had a greater proportion of males.

The genotype and allele distributions of FasL polymorphism in the cases and controls are shown in [Table 2](#t2){ref-type="table"}. The observed genotype frequencies was in agreement with Hardy--Weinberg equilibrium in the controls (χ^2^ = 2.663, *P* = 0.103). The frequencies of the TT, TC and CC genotypes were 27.8%, 44.4% and 27.8%, respectively, among the cases and 20.2%, 33.6% and 46.2%, respectively, among the controls. The frequencies of C alleles in ESCC patients and control samples were 0.50 and 0.63, respectively.

Effect modification of the associations of the SNP with ESCC
------------------------------------------------------------

Logistic regression analysis was used to estimate associations between the genotypes and risk of ESCC ([Table 2](#t2){ref-type="table"}). When stratified by age and gender, the FasL gene -844 CC genotype was associated with a decreased risk for the development of ESCC (Adjusted OR = 0.436, 95% CI = 0.271--0.702, *P* = 0.001) compared with TT genotype. The C haplotype remained a significant protective role for ESCC (Adjusted OR = 0.555, 95% CI = 0.419--0.735, *P* = 0.000), which was comparable to that of T.

Prognostic significance of FasL polymorphism
--------------------------------------------

The relationship of ESCC clinical pathological parameters and FasL -844 SNP was compared ([Table 3](#t3){ref-type="table"}). There were no significant differences between the gene polymorphism and age, gender, tumor grade, tumor site, lymph node metastasis, cardiac involvement, vascular invasion. While FasL -844 C/T showed significant modification of genotype and risk by the tumor length, T stage and TNM stage. FasL CC versus TT was dangerous, adjusted OR = 3.300 (1.572--6.929), *P* = 0.002; adjusted OR = 2.494 (1.242--5.007), *P* = 0.010; adjusted OR = 2.179 (1.063--4.468), *P* = 0.033, respectively ([Table 4](#t4){ref-type="table"}).

Association of -844T/C polymorphism and ESCC in selected population
-------------------------------------------------------------------

Patients with ESCC and healthy group were stratified by age to explore whether FasL -844T/C polymorphism was associated with ESCC in this selected population of patients ([Table 5](#t5){ref-type="table"}). Genotype frequencies in two control subgroups (\<60, ≥60 years old) agreed with frequencies expected under the Hardy-Weinberg equilibrium (χ^2^ = 1.852, *P* = 0.174 and χ^2^ = 0.792, *P* = 0.373, respectively). With age \<60 years, the frequencies of the TT, TC and CC genotypes were 27.6%, 41.4% and 31.0%, respectively, among the cases and 20.5%, 33.5% and 54.0%, respectively, among the controls. There was no difference between the two groups. While, the frequencies of C alleles in ESCC patients and control samples were 60.2% and 51.1%, respectively, which had statistical difference.

For those over age 60, there were significant differences between the two groups about genotypes or alleles. The frequencies of the three genotypes were 27.4% (TT), 46.5% (TC) and 26.1% (CC), respectively, among the cases and 16.2% (TT), 42.9% (TC) and 40.9% (CC), respectively, among the controls. The frequencies of C alleles in ESCC patients and control samples were 75.2% and 51.1%, respectively.

We conducted further analyses to explore whether FasL -844T/C polymorphism was associated with clinical parameters in a selected population of patients ([Table 6](#t6){ref-type="table"}).

In univariate analysis for age \<60 years ([Table 7](#t7){ref-type="table"}), FasL -844 TC and CC genotype showed significant associations with T grade (OR = 3.333, 1.134--9.801, *P* = 0.029; OR = 5.833, 1.710--19.902, *P* = 0.005, respectively). With TT as reference, CC was significant with an OR of 0.308 (0.192--0.493), *P* = 0.000 but TC was not significant in Cardiac involvement.

For those over age 60, FasL -844 TC and CC genotype showed significant associations with sex (OR = 0.591, 0.506--0.690, *P* = 0.026; OR = 0.423, 0.326--0.548, *P* = 0.001, respectively). With TT as reference, CC was significant with an OR of 0.308 (0.192--0.493), *P* = 0.000 but TC was not significant in Cardiac involvement. The same situation was appeared in tumor length (OR = 4.000, 1.550--10.326, *P* = 0.004).

Association of -844T/C polymorphism and FasL expression
-------------------------------------------------------

Immunohistochemistry was carried out to research whether FasL -844 variation is able to modify the levels of expression of FasL ([Fig. 1](#f1){ref-type="fig"}). This SNP was correlated with FasL expression in ESCC patients\' normal esophagus region, cancer tissue and pericancerous tissue region ([Fig. 2](#f2){ref-type="fig"}). The protein expression in normal esophageal region was weak with only a higher rate of positive expression in CC genotype. No matter what the genotype is, there were FasL expression in cancer tissue and peficancerous tissue and compared with TT and TC genotypes, CC genotype carriers had higher FasL protein expression.

Association of -844T/C polymorphism and Fas -1377G/A polymorphism
-----------------------------------------------------------------

The genotype and allele distributions of FasL polymorphism in the cases and controls are shown in [Table 8](#t8){ref-type="table"}. When stratified by age and gender, the Fas gene -1377 AA genotype was associated with a decreased risk for the development of ESCC (Adjusted OR = 0.511, 95% CI = 0.283--0.921, *P* = 0.026) compared with GG genotype. The A haplotype remained a significant protective role for ESCC (Adjusted OR = 0.834, 95% CI = 0.727--0.956, *P* = 0.000), which was comparable to that of G. However, FasL -844 CC combining with Fas -1377 G allele is a protective factor for ESCC (Adjusted OR = 0.488, 95% CI = 0.320--0.743, *P* = 0.001) ([Table 9](#t9){ref-type="table"}).

Discussion
==========

The FasL gene maps on chromosome 1q23 and its product is a 40-kDa type II transmembrane protein. FasL which exists in cytotoxic T lymphocyte (CTL) and NK cells belongs to TNF family and works as an apoptotic agent. It can bounds Fas to activate target cell apoptosis. The FasL -844T/C polymorphism locates in the gene promoter. Higher basal expression of FasL is significantly associated with the FasL -844 C allele compared with the FasL-844 T allele. The C allele and its flanking sequence constitute CAAT box that is the binding site for CAAT Enhancer Binding Protein Beta (C/EBPβ), resulting in a significantly higher basal FasL expression in peripheral blood fibrocytes with luciferase reporter assay[@b8]. The FasL -844 T/C polymorphism may influence FasL expression level and FasL-mediated signaling pathway, and ultimately, the susceptibility to cancer. Many types of tumors express FasL, and aberrant gene expression has been reported to do with cervical carcinogenesis and tumor progression[@b9][@b10][@b11]. Heightened FasL expression would improve tumor cells to counter attack the immune system by killing Fas-sensitive lymphocytes, thereby contributing to cancer development. High FasL expression in tumor tissues has been linked to poor prognosis in various human carcinomas[@b12][@b13][@b14][@b15][@b16][@b17]. An animal model study indicated that after neutralized by human FasL antibody, tumor load and colony formation of tumor cells significantly reduced[@b18].

There were two mechanisms for *Fas-FasL* system participating in immune escape: (I) tumor cells express FasL to counterattack tumor-infiltrating T cells, which results in immune escape[@b19][@b20][@b21][@b22]; (II) In tumor microenvironment, Fas-FasL mediated activation-induced cell death (AICD) in tumour-infiltration lymphocyte (TIL) apoptosis. AICD is an important mechanism responsible for the increased apoptosis rate among the tumor-infiltrating lymphocytes, leading to the transformed cells escaping the elimination by anticancer immunosurveillance and contributes to cancer development. The FasL --844C allele, which had higher expression of FasL on T cells, was associated with an enhanced rate of AICD of T cells, which may result in less powerful immune surveillance and increase the susceptibility to cancer[@b23].

It had been reported that FasL-844T/C gene polymorphism is a risk factor for cervical cancer[@b23], lung cancer[@b24], bladder cancer[@b25], breast cancer[@b26], pancreatic cancer[@b27]. One meta-analysis suggested that the FasL -844 T/C polymorphism was associated with cancer risk[@b28]. The C allele is a low-penetrant cancer susceptibility marker for cancer development while the T allele has a possible protective effect on cancer risk. This association between the SNP and the cancer risk was obvious among Asians. However, Ter-Minassian *et al*. reported that subjects under the age 60 years with the *FasL* -844 TC or TT genotype had higher risk for non-small cell lung cancer compared to the CC genotype[@b29]. Lei *et al* found that compared with -844 CC carriers, CT or TT carriers had a sigificant increased risk of the prevalence of second primary cancer after head and neck squamous cell carcinoma[@b30]. Sun *et al.* showed that individuals with both Fas -1377AA and FasL -844 CC genotypes had a higher risk for developing esophageal squamous-cell carcinoma compared with those with both Fas -1377GG and FasL -844 TT genotypes[@b6]. We investigated the association between the FasL−844T/C polymorphism on the risk of ESCC in a south China population. In this study, the polymorphism exhibited apparent relationship with the risk of ESCC. Compared with T allele, C allele is protective factors for ESCC susceptibility.

The large case-control study of the association FasL -844 T/C polymorphism with non-small cell lung cancer (NSCLC) found that the association of the FasL -844 SNP in North American Caucasians that appears to be significant in individuals, 60 years old and shows statistically significant effect modification with different measures of age[@b29]. Therefore, we stratified the subjects by age (less than 60 years old and greater than or equal to 60 years old. Compared with the control group, there was significant difference in allele frequencies, but no difference in genotypes of patients less than 60 years old. While, there were significant differences in allele and genotypes of patients greater than 60 years old. That means the presence of the CC genotype may be a protective factor for ESCC in these subgroup patients. The C allele has been shown to be associated with higher FasL expression compared with the T allele and it was reported that FasL also expressed in esophageal mucosal. We speculate that patients greater than 60 years old with the CC genotype may be have higher expression level of FasL in esophageal mucosa and immune cells. This may play a killing effect to atypical cells of the esophagus to prevent the formation of esophageal cancer. It is relevant to suggest that esophageal cancer screening should be carried out regularly among TT carriers over the age of 60.

Secondly, there were relationship between -844T/C SNP and ESCC clinicopathological parameters. We found that FasL gene polymorphism of esophageal cancer patients is related to T stage, TNM stage, and tumor length. CC genotype is a risk factor. The tumor with CC genotype is longer and has deeper invasion ability, and reached an advanced stage more easily than other genotypes. That is to say FasL -844CC genotype is shown to be a malignant factor for ESCC. Immune cells of healthy people with CC genotype express more FasL protein, which will kill the mutant cells to prevent the occurrence of cancer. After tumorigenesis, cancer cells increase FasL expression to kill more immune cells and promote tumor development. People with CC genotype are not likely to suffer from ESCC. However, once fall ill, tumor will develop faster and get higher degree of malignancy than other genotypes.

To explore the relationship of FasL -844T/C SNP and ESCC clinicopathological parameters in different ages, we stratified patients by age. CC phenotype is a protective factor in female patients regardless of greater than or equal to 60 years old or less than 60 years old, because male patients had a greater proportion of smokers. Over half of Chinese males over 15 years old are smokers, compared to only 2.4% of women. It had been reported that smoking and alcohol drinking were associated with esophageal cancer risk among Chinese men, but not among Chinese women[@b31]. Therefore, CC phenotype as a protective factor for women may have a certain relationship with smoking factors. Smoking may modify the association of the FasL -844 SNP with ESCC. Besides sex, FasL -844 CC showed significant modification of genotype and risk by cardiac involvement in less than 60 years old patients. We speculate that CC carriers less than 60 years old may have strong mucosal immune function of gastrointestinal tract that is easy to prevent tumor to invade cardia. While, CC genotype is a risk factor in T grade (T1 + T2 vs T3 + T4). Among older patients, CC is a risk factor in tumor length and Cardiac involvement. For patients with CC genotype less than 60 years old, tumor cells express more FasL to kill immune cells. Young adults have stronger immune response and immunosuppression is relatively stronger than elder patients leading to more aggressive and much later stage. For patients older than 60 years, the immune function especially the gastrointestinal mucosal immune function, is weakened resulting in more length of cancer. In brief, their tumors will progresse quickly and malignantly in case elder patients with CC genotype get sick.

The expression of FasL in patients was analyzed to conform that the variation of -844T/C in FasL gene is able to significantly modify the levels of expression of FasL. The polymorphism of FasL -844 affects the expression of FasL protein in patients\' normal esophageal epithelium, esophageal carcinoma and pericancerous tissue cells. FasL -844CC genotype were accompanied by high expression of FasL. Cells with high level of FasL would kill atypical precancerous cells more rapidly. That is why FasL-844 C allele is a protection factor for ESCC.

According to the previous study[@b32], other polymorphisms of death pathway genes (in particular Fas) might interfere with the functional effect by -844T/C polymorphisms FasL. So, the polymorphism of Fas gene -1377 was analyzed to study whether susceptibility to esophageal cancer is influenced by FasL -844 SNP under the intervention of Fas -1377 SNP. We found that Fas -1377 AA genotype is a protection factor for ESCC. It was reported that Fas --1377A allele disrupt Sp1 transcription factor binding sites, and thus diminish promoter activity and decrease Fas gene expression[@b33].

FasL -844 polymorphism effects together with the contribution from the Fas -1377 polymorphism esophageal cancer susceptibility were considered. FasL -844 CC combining with Fas -1377 GG + GA is a protective factor for ESCC. Cells with Fas -1377 G allele express Fas protein normally. If these cells had FasL -844 CC genotype which results in high expression FasL protein, compared with FasL -844 T carriers, it will kill atypical precancerous cells more rapidly to avoid tumorigenesis. On the contrary, cells, including cancer cells with Fas -1377 G allele express low level Fas that will cause immune escape. In this case, even FasL -844 CC genotype induces high expression of FasL, nor will it plays a protective role in susceptibility to ESCC. Among the same FasL -844 SNP carriers, Fas -1377 polymorphism\'s effect is small to susceptibility to ESCC.

In this study, we investigated the association between the FasL -844T/C polymorphism on the risk of ESCC in south China. We found that C allele was associated with a significantly decreased risk of ESCC. FasL -844 CC combining with Fas -1377 G allele is a protective factor for ESCC. However, younger patients would suffer more malignant pathologic T grade if they were FasL -844 CC carriers. This polymorphism affects the expression of FasL protein in patients. Further research will be carried out to study the mechanism of above conclusions.

Methods
=======

Subjects
--------

Patients with histopathologically confirmed esophageal squamous cell carcinoma (n = 248) were recruited from Zhejiang Cancer Hospital, affiliated hospital of Zhejiang Medical College, China between January 2008 and October 2011. Control subjects (n = 298) were cancer-free individuals who were randomly selected from medical examination center. All subjects were unrelated ethnic Han Chinese and residents in south China. There was no sex and age restriction. Before recruitment, a standard questionnaire was administered through face-to-face interviews by trained interviewers to obtain information on demographic data and related factors. At recruitment, written informed consent was obtained from each subject to consent to participate in the study and to allow their biological samples to be genetically analyzed. This research was approved by Medical Ethics Committee, Zhejiang Cancer Hospital. The experimental protocol was carried out strictly according to the guidelines.

All patients underwent esophagectomy and had detailed metastatic data. The tumor staging was determined according to the 1997 American Joint Committee on Cancer (AJCC). TNM stage system and the tumor grade were according to WHO guidelines. The presence or absence of lymph node metastasis was evaluated according to the tumor node metastasis classification on the basis of postoperative histopathologic examination of esophageal tumor specimens. Other clinical data (age at diagnosis, sex, tumor length and location), tumor biological data (Nerve involvement, Cardiac involvement, Vascular tumor thrombus) were also documented.

Genotyping
----------

After signing informed consent forms, each subject donated 3 ml of blood to be used for genomic DNA extraction.

Genomic DNA was extracted from peripheral blood using Blood Genome DNA Extraction Kit (Takara Biotechnology Co. Ltd., Dalian). The -844T/C polymorphism of FasL was detected using PCR-RFLP. DNA fragments were amplified in a total volume of 100 ul PCRs containing PCR Premix 50 uL (Bioteke corporation, Beijing, China), forward primer (5′- CAGCTACTCGG AGGCCAAG - 3′) 1 uL, reverse primer (5′- GCTCTGAGGGGAGAGACCAT --3′) 1 ul, DDW 46 uL and DNA 2 uL. Amplification was carried out under the following condition: 1 cycle of 2 min at 95°C, 35 cycles of 30 sec at 94°C, 30 sec at 62°C, and 45 sec at 72°C, followed by 7 min at 72°C. Amplified products were digested with BsrDI (Fermentas, Thermo Fisher Scientific Inc.) at 55°C for 4 h. All products were loaded onto 3% MS-6 Agarose (Takara Biotechnology Co. Ltd., Dalian), and electrophoresed. Bands were visualized and typed after GelRed (Biotium Company, U.S) staining.

The PCR product amplified for the polymorphism was 410 bp. The BsrDI restriction enzymes were used to distinguish -844T/C, resulting in 122 bp and 104 bp fragments in the presence of the -844T allele. The polymorphism analysis was performed by two persons independently in a blind fashion. More than 10% of the samples were randomly selected for confirmation, and the results were 100% concordant.

Fas -1377G/A polymorphism in promoter region was also detected with PCR-RFLP. The primers for amplification were 5′- TGTGTGCACAAGGCTGGCGC--3′ for forward primer and 5′- TGCATCTGTCACTGCACTTACCACCA--3′ for reverse primer, which produce 122 bp fragment. To introduce a restriction endonuclease site, 3′end of forward primer was changed from CAC to CGC, which created a BstUI site. The procedure of amplification was the same as above. After PCR, BstUI (New England Biolabs, Beverly, MA) digestion generated the following fragments: Fas --1377G allele, fragments of 104 bp and 18 bp.

Immunohistochemistry
--------------------

Paraffin-embedded sections of esophageal carcinoma tissue, pericancerous tissue and normal tissue of 248 ESCC patients which stored in pathology department of our hospital were collected to do immunohistochemical stains. Antibody for human FasL (Santa Cruz Biochemistry Inc., Santa Cruz, CA) was used to detect FasL protein on above tissue sections. Immunohistochemical procedures were performed as described previously[@b34]. The intensity of staining was graded as negative (−), weakly positive (±), positive (+), moderately positive (++), or strongly positive (+++).

Statistical analyses
--------------------

Values were expressed as mean ± SD or percent. To check for genotyping error, we examined departure from Hardy--Weinberg equilibrium (HWE) in controls, using χ^2^ test. χ^2^ test analysis was used to detect this SNP in patients with esophageal cancer and health individuals. T test and χ2 test were used to detect age and sex in the two groups, respectively.

Association between FasL -844 T/C or Fas -1377 G/A polymorphism and ESCC was assessed using χ^2^ test. ESCC risk was estimated by odds ratios (OR) and 95% confidence intervals (CI) using a conditional logistic regression model controlling for age, and gender. This codominant model is defined as heterozygotes (1 variant genotype) versus wild-type (0 variant genotype) or homozygotes (2 variant genotype) versus wild-type.

The relationships of the SNP with the clinicopathologic parameters of patients were analyzed by χ^2^ test. We used binary logistic regression (Ascendant Wald method) with each parameter as dependant variable and genotypes of FasL -844 T/C polymorphism with other clinical parameters as independent variables. Clinical pathological parameters were dichotomised as follows: grading (well and moderately differentiation versus poorly differentiation), T grade (T1--T2 versus T3--T4), Location of the tumor (Epimere- midportion versus hypomere), tumor length (less than 5 cm versus equal and greater than 5 cm), lymphnode metastasis, nerve involvement, cardiac involvement and vascular tumor thrombus (positive versus negative).

For stratified analyses, we created indicator variable of age greater or less than 60 years old. Then the above statistical analyses were carried out at different age groups.

All statistical testing was done at the two-sided 0.05 level with SPSS 16.0 software.
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![Immunohistochemical stainings of FasL.\
(a) normal tissue with negative staining; (b) normal tissue with weakly positive staining; (c) pericancerous tissue; (d) carcinoma tissue.](srep03866-f1){#f1}

![FasL expression with FasL -844 SNP in normal tissue, pericancerous tissue and carcinoma tissue of patients group (n = 248).\
(a) normal tissue, χ2 = 1.047 × 10^2^ *P* = 0.000; (b) pericancerous tissue, χ2 = 75.451 *P* = 0.000; (c) carcinoma tissue, χ2 = 1.016 × 10^2^ *P* = 0.000.](srep03866-f2){#f2}

###### Baseline clinical characteristics of cases and controls

                                             Cases       Controls
  --------------------------------------- ------------ ------------
  n                                           248          297
  Men[\*](#t1-fn1){ref-type="fn"}             215          179
  Age(year)[\*](#t1-fn1){ref-type="fn"}    61.4 ± 6.5   56.6 ± 7.9

\**P* \< 0.05.

###### Genotypic and allelic frequencies of FasL gene -844 among case patients and control subjects and the association of this SNP with ESCC risk

                 Cases (%) n = 248   Controls (%) n = 297    χ^2^                    *P*                    Crude OR (95%CI)        *P*      Adjusted OR[\#](#t2-fn2){ref-type="fn"} (95% CI)                   *P*
  ------------- ------------------- ---------------------- -------- ------------------------------------- --------------------- ----------- -------------------------------------------------- -------------------------------------
  *Genotypes*                                                                                                                                                                                                     
  TT                 69 (27.8)             52(17.5)                                                                 1                                               1                                             
  TC                110 (44.4)            128(43.1)         11.827   0.003[\*\*](#t2-fn1){ref-type="fn"}   0.957(0.599--1.527)     0.852                   1.081(0.640--1.826)                                 0.771
  CC                 69 (27.8)            117 (39.4)                                                       0.436(0.271--0.702)   0.001\*\*                 0.425(0.255--0.708)                  0.001[\*\*](#t2-fn1){ref-type="fn"}
  *Alleles*                                                                                                                                                                                                       
  T allele          248 (50.0)            232 (39.1)        13.13    0.000[\*\*](#t2-fn1){ref-type="fn"}            1                                               1                                             
  C allele          248 (50.0)            362 (60.9)                                                       0.641(0.504--0.816)   0.000\*\*                 0.597(0.460--0.776)                  0.000[\*\*](#t2-fn1){ref-type="fn"}

\*\**P* \< 0.01.

^\#^. Adjusting for age and gender.

###### Distribution of selected characteristics of the patient cohort

                                      Cases n = 248                                                     
  ------------------------- ---------------------------------- ---------- ---------- ---------- ------- -----------------------------------
  Age(year)                                \<60                 26(10.5)   37(14.9)   28(11.3)   0.920                 0.631
  ≥60                                    43(17.3)               73(29.4)   41(16.5)                                       
  sex                                      male                 58(23.3)   94(37.9)   59(23.8)   0.079                 0.961
  female                                 11(4.4)                16(6.5)    10(4.0)                                        
  Grading                    well- moderately differentiation   53(21.4)   85(34.3)   51(20.6)   0.283                 0.868
  poorly differentiation                 16(6.5)                25(10.1)   18(7.3)                                        
  T Grade                                 T1--T2                37(5.6)    49(12.5)   20(3.6)    8.820   0.012[\*](#t3-fn1){ref-type="fn"}
  T3--T4                                 32(12.9)               61(24.6)   49(19.8)                                       
  TNM stage                             I--II--III              54(21.8)   75(30.2)   40(16.1)   6.543   0.038[\*](#t3-fn1){ref-type="fn"}
  IV                                     15(6.0)                35(14.1)   29(11.7)                                       
  Location of the tumor            Epimere- midportion          41(16.5)   58(23.4)   40(16.1)   1.065                 0.587
  hypomere                               28(11.3)               53(21.4)   29(11.7)                                       
  Length                                   \<5                  52(21.0)   70(28.2)   35(14.1)   9.025   0.011[\*](#t3-fn1){ref-type="fn"}
  ≥5                                     17(6.9)                40(16.1)   34(13.7)                                       
  Lymphnode metastasis                     Yes                  34(13.7)   65(26.2)   35(14.1)   2.066                 0.356
  No                                     35(14.1)               45(18.1)   34(13.7)                                       
  Nerve involvement                        yes                  48(19.4)   77(31.0)   48(19.4)   0.005                 0.997
                                            no                  21(8.5)    33(13.3)   21(8.5)                             
  Cardiac involvement                      yes                  49(19.8)   88(35.5)   53(21.4)   1.913                 0.384
  no                                     20(8.1)                22(8.9)    16(6.5)                                        
  Vascular tumor thrombus                  yes                  58(23.4)   85(34.3)   56(22.6)   1.282                 0.527
  no                                     11(4.4)                25(10.1)   23(9.3)                                        

![](srep03866-t2)

\**P* \< 0.05.

###### Risk of ESCC tumor length, T grade and TNM stage according to FasL genotype

        Length     T grade                   TNM stage                                                                                                     
  ---- -------- -------------- ------------------------------------- ------- -------------- ------------------------------------- ------- ---------------- -----------------------------------
  TT      1                                                             1                                                            1                                       
  TC    1.748    0.893--3.421                  0.103                  1.439   0.787--2.634                  0.238                  1.680   (0.835--3.379)                 0.146
  CC    2.971    1.442--6.122   0.003[\*\*](#t4-fn2){ref-type="fn"}   2.833   1.402--5.722   0.004[\*\*](#t4-fn2){ref-type="fn"}   2.610   (1.238--5.500)   0.012[\*](#t4-fn1){ref-type="fn"}

\**P* \< 0.05.

\*\**P* \< 0.01.

###### Genotypic and allelic frequencies of FasL gene -844 in subgroups according to age

  n(%)        Genotype(Frequency)           Allele(Frequency)                                                                                                            
  ---------- --------------------- ----------------------------------- ----------------------------------- ----------- ----------- ------------------------------------- -----------
  \<60               Cases                         91                               26(28.6)                37(40.7)    28(30.8)                 89(48.9)                 93(51.1)
  Controls            192                       35(18.23)                           83(43.23)               74(38.54)   153(39.8)                231(60.2)                     
  χ^2^               4.195                        4.139                                                                                                                  
  *p*                0.123          0.042[\*](#t5-fn1){ref-type="fn"}                                                                                                    
  ≥60                Cases                         157                              43(27.4)                73(46.5)    41(26.1)                 159(50.6)                155(49.4)
  Controls            105                       17(16.2)                            45(42.9)                43(40.9)    79(37.6)                                          131(62.4)
  χ^2^                                                                                7.951                                                        8.602                       
  *p*                                                                   0.019[\*](#t5-fn1){ref-type="fn"}                           0.003[\*\*](#t5-fn2){ref-type="fn"}        
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\**P* \< 0.05.

\*\**P* \< 0.01.

###### Distribution of selected characteristics of patients subgroups cohort

                              \<60                    ≥60                           
  ------------------------- -------- ------------------------------------- -------- -------------------------------------
  sex                        11.052   0.004[\*\*](#t6-fn2){ref-type="fn"}   7.385     0.025[\*](#t6-fn1){ref-type="fn"}
  Grading                    13.305    0.010[\*](#t6-fn1){ref-type="fn"}    3.554                   0.470
  T Grade                    17.976   0.001[\*\*](#t6-fn2){ref-type="fn"}   8.494                   0.075
  TNM stage                  22.716   0.001[\*\*](#t6-fn2){ref-type="fn"}   15.906    0.014[\*](#t6-fn1){ref-type="fn"}
  Location of the tumor      2.962                   0.564                  3.063                   0.547
  Length                     1.826                   0.401                  8.383     0.015[\*](#t6-fn1){ref-type="fn"}
  Lymph node metastasis      0.878                   0.645                  5.067                   0.079
  Nerve involvement          0.499                   0.779                  0.298                   0.862
  Cardiac involvement        15.721   0.000[\*\*](#t6-fn2){ref-type="fn"}   10.085   0.006[\*\*](#t6-fn2){ref-type="fn"}
  Vascular tumor thrombus    3.817                   0.148                  0.034                   0.983

\**P* \< 0.05.

\*\**P* \< 0.01.

###### Genotype frequencies of FasL -844 T/C polymorphism in relation to pathological indices of ESCC severity in patients according to the age (\<60 *vs* ≥60)

                         \<60   ≥60                                                                                                                    
  --------------------- ------ ----- ----------------------------------- ------------------------------------- --- ----------------------------------- -------------------------------------
  sex                     OR     1                  0.333                                0.357                  1                 0.591                                0.423
                          CI                    0.100--1.112                         0.238--0.536                             0.506--0.690                         0.326--0.548
                         *P*                        0.074                 0.000[\*\*](#t7-fn2){ref-type="fn"}       0.026[\*](#t7-fn1){ref-type="fn"}   0.001[\*\*](#t7-fn2){ref-type="fn"}
  Grading                 OR     1                  1.000                                0.857                  1                 1.193                                1.091
                          CI                    0.303--3.296                         0.235--3.129                             0.481--2.962                         0.386--3.079
                         *P*                        1.000                                0.816                                    0.704                                0.869
  T grade                 OR     1                  3.333                                5.833                  1                 0.785                                1.575
                          CI                    1.134--9.801                         1.710--19.902                            0.374--1.650                         0.666--3.726
                         *P*          0.029[\*](#t7-fn1){ref-type="fn"}   0.005[\*\*](#t7-fn2){ref-type="fn"}                     0.523                                0.301
  TNM stage               OR     1                  2.143                                2.400                  1                 1.019                                2.062
                          CI                    0.687--6.680                         0.726--7.935                             0.441--2.351                         0.839--5.073
                         *P*                        0.189                                0.151                                    0.966                                0.115
  Length                  OR     1                  1.500                                2.400                  1                 2.298                                4.000
                          CI                    0.473--4.761                         0.726--7.935                             0.962--5.487                         1.550--10.326
                         *P*                        0.491                                0.151                                    0.061                 0.004[\*\*](#t7-fn2){ref-type="fn"}
  Cardiac involvement     OR     1                  0.500                                0.308                  1                 0.900                                3.611
                          CI                    0.173--1.441                         0.192--0.493                             0.298--2.722                         1.243--10.489
                         *P*                        0.199                 0.000[\*\*](#t7-fn2){ref-type="fn"}                     0.852                  0.018[\*](#t7-fn1){ref-type="fn"}

\**P* \< 0.05.

\*\**P* \< 0.05.

###### Genotypic and allelic frequencies of Fas gene -1377 among case patients and control subjects and the association of this SNP with ESCC risk

                 Cases (%) n = 248   Controls (%) n = 297   χ^2^                   *P*                   Crude OR (95%CI)                    *P*                  Adjusted OR[\#](#t8-fn3){ref-type="fn"} (95% CI)                   *P*
  ------------- ------------------- ---------------------- ------- ----------------------------------- --------------------- ----------------------------------- -------------------------------------------------- -------------------------------------
  *Genotypes*                                                                                                                                                                                                                          
  GG                 126(50.8)            120(40.4)                                                              1                                                                       1                                             
  GA                 97(39.1)             135(45.5)         6.330   0.042[\*](#t8-fn1){ref-type="fn"}   0.684(0.477--0.982)   0.040[\*](#t8-fn2){ref-type="fn"}                 0.694(0.470--1.026)                                 0.067
  AA                 25(10.1)              42(14.1)                                                     0.567(0.326--0.987)   0.045[\*](#t8-fn2){ref-type="fn"}                 0.511(0.283--0.921)                   0.026[\*](#t8-fn1){ref-type="fn"}
  *Alleles*                                                                                                                                                                                                                            
  G allele           349(70.4)            375(63.1)         6.338   0.012[\*](#t8-fn2){ref-type="fn"}            1                                                                       1                                             
  A allele           147(29.6)            219(36.9)                                                     0.849(0.748--0.965)   0.012[\*](#t8-fn2){ref-type="fn"}                 0.834(0.727--0.956)                  0.000[\*\*](#t8-fn2){ref-type="fn"}

\**P* \< 0.05.

\*\**P* \< 0.01

#\. Adjusting for age and gender.

###### Risk of ESCC associated with FasL -844genotypes by Fas -1377genotypes

  Genotypes                                                             
  ----------- --------- ------------ ------------ --------------------- -------------------------------------
  TT + TC      GG + GA   163 (65.7)   154 (51.9)            1                              
  TT + TC        AA       16 (6.5)     26 (8.8)    0.513(0.251--1.047)                  0.067
  CC           GG + GA   60 (24.2)    101 (34.0)   0.488(0.320--0.743)   0.001[\*\*](#t9-fn2){ref-type="fn"}
  CC             AA       9 (3.6)      16 (5.4)    0.422(0.174--1.021)                  0.056

\**P* \< 0.05.

\*\**P* \< 0.01.

^\#^. Adjusting for age and gender.
